Engineered immune cells and application thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANJING BIOHENG BIOTECH CO LTD
- Publication Date
- 2020-12-11
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of immunotherapy. More specifically, the present invention relates to an engineered immune cell expressing (i) a chimeric receptor, and (ii) exogenous CCL3, CCL4 and / or CCL5 genes. More preferably, said chimeric receptor is a chimeric antigen receptor or T cell receptor. Background technique
[0002] Tumor immunotherapy mainly relies on autoimmunity to eliminate tumor cells by regulating the human immune system and tumor microenvironment. The immune system is a unified whole, and innate immunity also plays a very important role in tumor immunity.
[0003] Some antigen-presenting cells, such as dendritic cells and macrophages, are the bridge between innate immunity and acquired immunity. Antigen-presenting cells can recognize tumor antigens and present them to the adaptive immune system, activate tumor-specific T cells, and then clear the tumor. Therefore, increasing the effect of the immune system on killing tumor...